Navigation Links
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
Date:11/6/2009

WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at the Hotel Sofitel in New York City. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc.( ® )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(®). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.

SOURCE DUSA Pharmaceuticals, Inc.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
10. Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets
11. Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 , ... ... and numeral energies can describe personality traits in humans. Using presidential candidate Donald ... their name and vitality. , “AstroNumerology is not about adding numbers up,” ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Interest is on ... screening tool and as an orthogonal tool for RNAi hit validation. A key reason ... specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The ... on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria ... the country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising Age has ... statement solutions provider, for the tenth consecutive year as a Top 20 Marketing ... Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. ...
(Date:5/31/2016)... ... 2016 , ... Super Powder, a supplement produced by Prox Formulas for providing ... athletes, continues to transform the nutritional supplement industry by providing a safe, natural approach ... amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit ...
Breaking Medicine News(10 mins):